Benzinga - by Benzinga Insights, Benzinga Staff Writer.
ERIC SEMLER, Board Member at Semler Scientific (NASDAQ:SMLR), reported acquisition of company stock options on May 29, according to a new SEC filing.
What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, SEMLER, Board Member at Semler Scientific, acquired stock options for 27,000 shares of SMLR. These options provide SEMLER with the right to purchase the company's stock at $23.32 per share.
During Thursday's morning session, Semler Scientific shares up by 3.13%, currently priced at $33.25. Considering the current price, SEMLER's 27,000 shares have a total value of $268,110.
All You Need to Know About Semler Scientific Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
Semler Scientific: Financial Performance Dissected Revenue Growth: Semler Scientific's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -12.65%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
- Gross Margin: The company sets a benchmark with a high gross margin of 92.16%, reflecting superior cost management and profitability compared to its peers.
- Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.88.
Market Valuation:
- Price to Earnings (P/E) Ratio: The P/E ratio of 11.58 is lower than the industry average, implying a discounted valuation for Semler Scientific's stock.
- Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.81, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio of 6.77 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Relevance of Insider Transactions Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
The Insider's Guide to Important Transaction Codes When dissecting transactions, the focal point for investors is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Semler Scientific's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.